Navigation Links
First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conference
Date:7/6/2011

PHOENIX, Ariz. July 6, 2011 A first-of-its-kind study of a patient with lung cancer who never smoked will be presented today by TGen and the Virginia G. Piper Cancer Center at Scottsdale Healthcare at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

Researchers for the first time sequenced the entire DNA and RNA of a patient with metastatic adenocarcinoma of the lung, said Dr. Glen Weiss, the first author of the study, which will be published in a special supplement of the Journal of Thoracic Oncology. Dr. Weiss also is Director of Thoracic Oncology at Virginia G. Piper Cancer Center Clinical Trials, a partnership between TGen and Scottsdale Healthcare that treats cancer patients with promising new drugs.

The patient is a 61-year-old woman who never smoked whose lung cancer had entered her bloodstream and spread to other parts of her body. She had been treated with several types of chemotherapy.

The study, Advanced Never Smoker Adenocarcinoma of the Lung: Report of paired normal and tumor whole genome and transcriptome sequencing, will be presented at the conference today, July 6. The study used Whole Genome Sequencing (WGS), also called Next-Generation Sequencing (NGS), to look at all 3 billion chemical bases of the patient's normal, as well as the patient's tumor, DNA.

The study went further by examining the normal and tumor RNA for whole transcriptome sequencing, which can reveal the possible defects in how proteins are synthesized. This provided an even more intricate view of the tumors biological make up and what might have led to her cancer.

"Evidently, this is very exciting. Next-Generation Sequencing now offers us the ability to survey the global landscape of cancer," said Dr. John Carpten, Director of TGen's Integrated Cancer Genomics Division and senior author of the presentation.

The results of the patient's sequencing were discussed with her treating oncologist and may
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. The loudest animal is recorded for the first time
2. New study documents first cookiecutter shark attack on a live human
3. First joint ESC/EAS guidelines for the management of dyslipidaemias
4. Prodigal plankton species makes first known migration from Pacific to Atlantic via Pole
5. Elsevier and ADSA announce winners of first annual Journal of Dairy Science Most Cited Awards
6. First genetic mutation linked to heart failure in pregnant women
7. First diagnostic test for hereditary childrens disease
8. First wood-digesting enzyme found in bacteria could boost biofuel production
9. First-of-its-kind fluorescence map offers a new view of the worlds land plants
10. Biochemist David Deamer explores how life began in new book, First Life
11. Registration opens for first Middle East and Africa osteoporosis meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... World Osteoporosis Day events today in Brussels. This year,s ... is a global call to take charge and improve ... is a disease that can be largely prevented through ... long run reducing healthcare budgets as well as preventing ...
... mildly lame sheep, but many do not take steps to ... and treating these animals. A study in the open access ... provide evidence for the accuracy of farmers, reporting of lameness, ... minimise footrot and other infectious foot conditions in their flocks. ...
... of Parkinson,s disease patients had insufficient levels of vitamin ... of Medicine. The fraction of Parkinson,s patients ... than patients with Alzheimer,s disease (41 percent) or healthy ... in the October issue of Archives of Neurology ...
Cached Biology News:IOF calls on European citizens to stand tall and speak out for their bones 2IOF calls on European citizens to stand tall and speak out for their bones 3Farmers can spot lame sheep, but fail to prevent footrot spread 2Lack of vitamin D linked to Parkinson's disease 2Lack of vitamin D linked to Parkinson's disease 3
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... GenomeDx Biosciences today announced that a new ... genomic test for prostate cancer, was able to predict ... radical prostatectomy without adjuvant therapy. Although rapid metastasis in ... tumor genomics to identify these men who have a ... advance. The study has been published online by ...
(Date:12/22/2014)... ITRA Global, one of the largest ... real estate, has further expanded its global reach with ... Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman of ... Global / ACORPP (Australian Corporate Property and Projects) , ... property services to a wide range of clients in ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... S*BIO Pte Ltd today announced that it has ... of Singapore Award. Dr. Stephen Rhind, Senior Vice ... behalf of the company, from Mr. S. Iswaran, ... BioSpectrum awards recognize outstanding contributions to the growth ...
... Healthcare Conference on March 10 -- 29th Annual Cowen ... March 5 Gen-Probe Incorporated (Nasdaq: GPRO ... the Barclays Capital Global Healthcare Conference in Miami on ... and at the 29th Annual Cowen and Company Healthcare ...
... Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... quarter and year ended December 31, 2008. , "During ... Products Business and were able to sustain progress on ... year for TAXUS," said Dr. William Hunter, President and ...
Cached Biology Technology:S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award 2S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award 3Gen-Probe to Webcast Two Upcoming Investor Presentations 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 28
Zonula Adherens Sampler Kit 10 mu g each...
Purified anti-SOCS3...
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Biology Products: